157 related articles for article (PubMed ID: 16420067)
41. Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.
Kung PP; Huang B; Zhang G; Zhou JZ; Wang J; Digits JA; Skaptason J; Yamazaki S; Neul D; Zientek M; Elleraas J; Mehta P; Yin MJ; Hickey MJ; Gajiwala KS; Rodgers C; Davies JF; Gehring MR
J Med Chem; 2010 Jan; 53(1):499-503. PubMed ID: 19908836
[TBL] [Abstract][Full Text] [Related]
42. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
43. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.
Woodhead AJ; Angove H; Carr MG; Chessari G; Congreve M; Coyle JE; Cosme J; Graham B; Day PJ; Downham R; Fazal L; Feltell R; Figueroa E; Frederickson M; Lewis J; McMenamin R; Murray CW; O'Brien MA; Parra L; Patel S; Phillips T; Rees DC; Rich S; Smith DM; Trewartha G; Vinkovic M; Williams B; Woolford AJ
J Med Chem; 2010 Aug; 53(16):5956-69. PubMed ID: 20662534
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.
Zask A; Kaplan J; Toral-Barza L; Hollander I; Young M; Tischler M; Gaydos C; Cinque M; Lucas J; Yu K
J Med Chem; 2008 Mar; 51(5):1319-23. PubMed ID: 18269228
[TBL] [Abstract][Full Text] [Related]
45. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
Zhang H; Neely L; Lundgren K; Yang YC; Lough R; Timple N; Burrows F
Int J Cancer; 2010 Mar; 126(5):1226-34. PubMed ID: 19676042
[TBL] [Abstract][Full Text] [Related]
46. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
Burlison JA; Avila C; Vielhauer G; Lubbers DJ; Holzbeierlein J; Blagg BS
J Org Chem; 2008 Mar; 73(6):2130-7. PubMed ID: 18293999
[TBL] [Abstract][Full Text] [Related]
47. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.
Huang KH; Veal JM; Fadden RP; Rice JW; Eaves J; Strachan JP; Barabasz AF; Foley BE; Barta TE; Ma W; Silinski MA; Hu M; Partridge JM; Scott A; DuBois LG; Freed T; Steed PM; Ommen AJ; Smith ED; Hughes PF; Woodward AR; Hanson GJ; McCall WS; Markworth CJ; Hinkley L; Jenks M; Geng L; Lewis M; Otto J; Pronk B; Verleysen K; Hall SE
J Med Chem; 2009 Jul; 52(14):4288-305. PubMed ID: 19552433
[TBL] [Abstract][Full Text] [Related]
48. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.
Baruchello R; Simoni D; Grisolia G; Barbato G; Marchetti P; Rondanin R; Mangiola S; Giannini G; Brunetti T; Alloatti D; Gallo G; Ciacci A; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Guglielmi MB; Barbarino M; Foderà R; Pisano C; Cabri W
J Med Chem; 2011 Dec; 54(24):8592-604. PubMed ID: 22066525
[TBL] [Abstract][Full Text] [Related]
49. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
Schroeder GM; An Y; Cai ZW; Chen XT; Clark C; Cornelius LA; Dai J; Gullo-Brown J; Gupta A; Henley B; Hunt JT; Jeyaseelan R; Kamath A; Kim K; Lippy J; Lombardo LJ; Manne V; Oppenheimer S; Sack JS; Schmidt RJ; Shen G; Stefanski K; Tokarski JS; Trainor GL; Wautlet BS; Wei D; Williams DK; Zhang Y; Zhang Y; Fargnoli J; Borzilleri RM
J Med Chem; 2009 Mar; 52(5):1251-4. PubMed ID: 19260711
[TBL] [Abstract][Full Text] [Related]
50. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE
Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277
[TBL] [Abstract][Full Text] [Related]
51. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
52. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents.
Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907
[TBL] [Abstract][Full Text] [Related]
53. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.
Chiosis G; Lucas B; Shtil A; Huezo H; Rosen N
Bioorg Med Chem; 2002 Nov; 10(11):3555-64. PubMed ID: 12213470
[TBL] [Abstract][Full Text] [Related]
54. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
55. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297
[TBL] [Abstract][Full Text] [Related]
56. Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.
Zapf CW; Bloom JD; Li Z; Dushin RG; Nittoli T; Otteng M; Nikitenko A; Golas JM; Liu H; Lucas J; Boschelli F; Vogan E; Olland A; Johnson M; Levin JI
Bioorg Med Chem Lett; 2011 Aug; 21(15):4602-7. PubMed ID: 21715165
[TBL] [Abstract][Full Text] [Related]
57. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.
Nakamura T; Wada H; Kurebayashi H; McInally T; Bonnert R; Isobe Y
Bioorg Med Chem Lett; 2013 Feb; 23(3):669-72. PubMed ID: 23265901
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90).
Radanyi C; Le Bras G; Messaoudi S; Bouclier C; Peyrat JF; Brion JD; Marsaud V; Renoir JM; Alami M
Bioorg Med Chem Lett; 2008 Apr; 18(7):2495-8. PubMed ID: 18304811
[TBL] [Abstract][Full Text] [Related]
60. Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.
Patel HK; Grotzfeld RM; Lai AG; Mehta SA; Milanov ZV; Chao Q; Sprankle KG; Carter TA; Velasco AM; Fabian MA; James J; Treiber DK; Lockhart DJ; Zarrinkar PP; Bhagwat SS
Bioorg Med Chem Lett; 2009 Sep; 19(17):5182-5. PubMed ID: 19646870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
